创新药逆市崛起，冲击9月最强主线！高弹性港股通创新药ETF（520880）连涨4日，标的年内涨逾118%

Core Viewpoint - The Hong Kong stock market experienced increased volatility, with all three major indices declining, while innovative pharmaceuticals showed resilience, becoming a key focus in the market [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw its price rise over 2% at one point, closing up 1.22%, marking a four-day strong performance with a total trading volume exceeding 700 million yuan [1] - Major leading stocks in the sector performed well, with Kelun-Botai Biotech rising over 6% to reach a historical high, and other companies like CSPC Pharmaceutical and 3SBio also seeing gains [3] Group 2: Industry Opportunities - The expectation of a high interest rate cut by the Federal Reserve in September is anticipated to improve the investment environment, potentially leading to breakthroughs in the global innovative drug industry [3] - Since the beginning of the year, 83 licensing agreements for domestic innovative drugs have been reached, nearing last year's total, with a year-on-year increase of 57%, and the total amount involved reaching 84.531 billion USD, a significant increase of 185% compared to last year [3] Group 3: Upcoming Events - The World Lung Cancer Conference (WCLC) will take place from September 6-9, where Chinese scholars will present 35 oral reports, highlighting the clinical data of domestic new drugs [4] - The second half of the year will feature major conferences such as the European Society for Medical Oncology and the American Society of Hematology, which are expected to showcase key clinical data from Chinese innovative drugs [4] Group 4: ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown outstanding elasticity, with a year-to-date cumulative increase of 118.95%, leading among various innovative drug indices [6] - The ETF has recently seen a net inflow of 68.79 million yuan, with a total fund size of 1.18 billion yuan, making it the largest and most liquid ETF tracking the Hang Seng Stock Connect Innovative Drug Select Index [8]